Dr. Ronald B. Natale is the director of the Lung Cancer Clinical Research Program at the Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center in Los Angeles. Dr. Natale is internationally renowned for his clinical research in lung and genitourinary cancers. He has published more than 250 articles and abstracts, authored chapters on lung cancer in several books and presented results of his research at cancer research meetings all over the world. Dr. Natale has developed or co-developed some the most widely used chemotherapy regimens in the world for small cell and non-small cell lung cancers (such as cisplatin + etoposide and carboplatin + paclitaxel), targeted agents in lung cancer including gefitinib, erlotinib and vandetanib, and the neoadjuvant MVAC regimen for localized bladder cancer. He has received numerous awards in recognition of his contributions to the treatment of lung and genitourinary cancers and has been cited as one of the best cancer doctors by Los Angeles Magazine, Good Housekeeping and each edition of Best Doctors in America since its inception.
Dr. Natale was a tenured faculty member at the University of Michigan, where he also served as associate director of the Comprehensive Cancer Center, and at the University of Southern California, where he served as associate director of medical oncology. Immediately prior to his current position, he served as senior research advisor and director of the National Lung Cancer Research Program for Aptium Oncology, Inc. His current work focuses on targeted therapies in lung cancer and mechanisms of action and resistance.
Dr. Natale holds a B.S. from the University of Michigan and an M.D. from Wayne State University School of Medicine in Detroit, where he also completed his medical residency. He completed a fellowship in hematology/oncology at the Memorial Sloan-Kettering Cancer Center in New York City and a research fellowship at the National Cancer Institute in Bethesda, Md.